Prolia (denosumab) / Amgen 
Welcome,         Profile    Billing    Logout  
 110 Diseases   151 Trials   151 Trials   7120 News 


«12...6667686970717273747576...8687»
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK, Evenity (romosozumab) / Astellas, Amgen, UCB
    Review, Journal:  Balancing benefits and risks in the era of biologics. (Pubmed Central) -  Nov 7, 2019   
    To date, several risk mitigation strategies have been identified and implemented. The objective of the present perspective review is to examine the risk mitigation strategies of biologic treatments, with special focus on anti-tumor necrosis factors and denosumab.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK, zoledronic acid / Generic mfg., Asahi Kasei
    Mature Osteoblasts Promote Multiple Myeloma Survival through Cell-Cell Contact and Immune Modulation Mechanisms (Hall B, Level 2 (Orange County Convention Center)) -  Nov 7, 2019 - Abstract #ASH2019ASH_2645;    
    Taken together, using in vivo and in vitro models, we show that mature osteoblasts may have a negative regulatory impact on MM cells through cell-cell communication or immunomodulatory mechanisms. Expanding the osteoblast niche may provide novel therapeutic avenues to reduce disease burden and create an environment for long term tumor control.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Trial completion:  Investigating the Use of Prolia (Denosumab) in the Treatment of Acute Charcot Neuroarthropathy (clinicaltrials.gov) -  Nov 4, 2019   
    P3,  N=7, Completed, 
    Expanding the osteoblast niche may provide novel therapeutic avenues to reduce disease burden and create an environment for long term tumor control. Active, not recruiting --> Completed
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo
    Enrollment change, Trial withdrawal:  Knee Osteoarthritis Outcome Measures in Arthritic Patients With Osteoporosis (clinicaltrials.gov) -  Nov 3, 2019   
    P=N/A,  N=0, Withdrawn, 
    Changes of systemic bone turnover induced by switching BPs to DMAb or TPTD may affect not only systemic bone mass, but also local joint destruction, and its clinical relevance should be considered comprehensively. N=20 --> 0 | Not yet recruiting --> Withdrawn
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
    Journal:  Total spondylectomy for Enneking stage III giant cell tumor of the mobile spine. (Pubmed Central) -  Oct 29, 2019   
    TES with intralesional pediculotomy had a good surgical outcome even in patients with Enneking stage III spinal GCT, suggesting that minimal intralesional procedures could radically cure spinal GCTs. These slides can be retrieved under Electronic Supplementary Material.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
    Journal:  After the fall: improving osteoporosis treatment following hip fracture. (Pubmed Central) -  Oct 26, 2019   
    These results suggests a potential therapeutic role for ZA and denosumab in MC-associated LBP. Resident education and an electronic order set dramatically improved the percentage of patients meeting standard of care with osteoporosis pharmacotherapy following fragility fracture.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
    Journal:  Effects of bone remodeling agents following teriparatide treatment. (Pubmed Central) -  Oct 26, 2019   
    Patients who elected to discontinue osteoporosis treatment experienced a significant decline in the change in BMD compared to the change on teriparatide putting them at higher risk for recurrence of fragility fractures. Patients on denosumab following teriparatide had the largest increase in BMD.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
    Clinical, Clinical guideline, Review, Journal:  A proposal for an atypical femur fracture treatment and prevention clinical practice guideline. (Pubmed Central) -  Oct 25, 2019   
    Patients on denosumab following teriparatide had the largest increase in BMD. Clinical practice guidelines for the treatment and prevention of AFF will benefit clinicians who are frequently faced with having to make clinical decisions in patients requiring antiresorptive medications.
  • ||||||||||  zoledronic acid / Generic mfg.
    Trial completion, Adverse events:  Osteonecrosis of the Jaw (ONJ) and Infection Among Nordic Cancer Patients Treated With XGEVA (clinicaltrials.gov) -  Oct 24, 2019   
    P=N/A,  N=2560, Completed, 
    This study demonstrated a low occurrence of serious and opportunistic infections in patients with RA taking bDMARD, including patients with concurrent denosumab use. Active, not recruiting --> Completed
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
    Clinical, Journal:  Drug holidays in women treated for postmenopausal osteoporosis. (Pubmed Central) -  Oct 24, 2019   
    Active, not recruiting --> Completed In this Practice Pearl, the experience with long-term treatment of osteoporosis with bisphosphonates and denosumab will be reviewed as well as the effects of discontinuing therapy, providing the platform for recommendations about "drug holidays" for these medications.
  • ||||||||||  Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Aimovig (erenumab) / Amgen, Novartis
    Improvement in Cervical Radiculopathy by Erenumab During the Preventive Treatment of Migraine in a Patient with CKD () -  Oct 23, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_5895;    
    She was taking pantoprazole, sacubitril/valsartan, metoprolol, clonidine, aspirin, linagliptin, pravastatin, alirocumab, denosumab, gabapentin, pentoxifylline, calcitriol, erythropoietin, sevelamer and pain medications including narcotics...This incidental finding may suggest additional use of CGRP-inhibitor for the treatment of radiculopathy. Therefore, further researches are necessary to prove this hypothesis.
  • ||||||||||  dexamethasone / generics
    Fanconi Syndrome and Hypomagnesemia: An Overlooked Association or Diagnostic Entity? () -  Oct 23, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_5721;    
    One month prior she was treated with cyclophosphamide, bortezomib, dexamethasone, and denosumab...Oral replacements of electrolytes and Amiloride were started, with stabilization of electrolytes...As stated in the limited literature with this association, there is cellular injury at the nephron primarily at the proximal tubular cells impairing passive reabsorption of magnesium in Fanconi’s Syndrome. Underscoring this electrolyte disorder of this syndrome may better allow future clinicians to recognize hypomagnesemia in the setting of a non-anion gap metabolic acidosis and perhaps be considered as a diagnostic entity.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
    Biomarker, Clinical, Review, Journal:  Interventions for preventing bone disease in kidney transplant recipients. (Pubmed Central) -  Oct 23, 2019   
    It is uncertain whether bisphosphonate therapy or other bone treatments prevent other skeletal complications after kidney transplantation, including spinal deformity or avascular bone necrosis. The effects of bone treatment for children and adolescents after kidney transplantation are very uncertain.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
    BL1 Deciphering Stem and Progenitor Cells to Understand Breast Cancer (Hall 3) -  Oct 19, 2019 - Abstract #SABCS2019SABCS_2015;    
    Pre-clinical studies further indicate that it may be possible to target this ‘culprit’ cell with the RANKL inhibitor denosumab...Initial efforts have focused on BH3 mimetics, a new class of drug that targets the BCL-2 family of pro-survival proteins. This work is leading to early phase clinical trials, currently focused on patients with metastatic ER+ breast cancer.
  • ||||||||||  paclitaxel / Generic Mfg.
    Subungual metastasis of an endometrial carcinoma () -  Oct 16, 2019 - Abstract #ESGO2019ESGO_1231;    
    A weekly Carboplatinum and Paclitaxel chemotherapy with concomitant Denosumab was initiated...As confirmed by the literature, the occurrence of subungual metastasis is precursor to the rapid fatal progression of the disease. Beside the unexpected topography of the metastasis, the absence of an underlying bone involvement and the mild clinical manifestations were singular features of this progression pattern.
  • ||||||||||  Afinitor (everolimus) / Novartis
    Second line treatment in metastatic uterine pecoma () -  Oct 16, 2019 - Abstract #ESGO2019ESGO_1200;    
    We report the effect of pazopanib for a patient with metastatic uterine PEComa progressing on everolimus...For the bone metastasis denosumab was initiated...Conclusion Our report provides evidence that anti-angiogenic targeted therapy with pazopanib, a multi TKI, is an effective second line treatment for metastatic malignant PEComas progressing after mTOR inhibition. The toxicity profile of the association was acceptable in line with the previously reported toxicities of the respective drugs.
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK, Actonel (risedronate) / Sanofi
    Review, Journal:  Current Treatments and New Developments in the Management of Glucocorticoid-induced Osteoporosis. (Pubmed Central) -  Oct 15, 2019   
    Both zoledronic acid and Dmab have been proven to be superior to oral bisphosphonates like risedronate in improvement of bone mineral density...In some patients second-line drugs are started later in the disease course, with lower GC dosages and higher disease activity. As this is a paradox, we think it is a challenge for physicians and expert committees to develop an algorithm with clear indications in which specific patient groups second-line anti-osteoporotic drugs should or could be initiated as first-choice treatment.
  • ||||||||||  QL1206 (denosumab biosimilar) / Qilu Pharma
    Trial completion, Trial primary completion date:  Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Xgeva (clinicaltrials.gov) -  Oct 15, 2019   
    P1,  N=168, Completed, 
    As this is a paradox, we think it is a challenge for physicians and expert committees to develop an algorithm with clear indications in which specific patient groups second-line anti-osteoporotic drugs should or could be initiated as first-choice treatment. Active, not recruiting --> Completed | Trial primary completion date: Jun 2019 --> Nov 2018
  • ||||||||||  Prolia (denosumab) / Amgen, Daiichi Sankyo, GSK
    Hypervitaminosis D Secondary to Agaricus blazei Murrill Mushroom Supplementation: A Case Report (Exhibit Hall, Walter E. Washington Convention Center) -  Oct 14, 2019 - Abstract #KIDNEYWEEK2019KIDNEY_WEEK_4125;    
    Serial monitoring showed that the calcium levels steadily decreased, as well as the Vitamin D levels, although at a slower rate. This case highlights the importance of assessing the intake of all substances, not only prescribed medications, and the potential danger of the ingestion of unlicensed herbal supplements.